Six IPOs raised $2.9 billion this week. Four traded up over 40%, and none finished the week below issue. Spun out of Eli Lilly, Elanco Animal Health (ELAN) priced above its range to raise $1.5 billion. The company popped 50% on its...read more
Y-mAbs Therapeutics, a Phase 2 biotech developing monoclonal antibody therapies for pediatric cancers, raised $96 million by offering 6.0 million shares at $16, the high end of the $14 to $16 range. The company had originally planned to raise $80 million by...read more
Eight IPOs are on the docket for the week ahead, raising a whopping $3.3 billion. Three deals are raising $500 million, but fast-growing ticketing platform Eventbrite (EB) should generate the most excitement. The largest, ...read more
Y-mAbs Therapeutics, a phase 2 biotech developing monoclonal antibody therapies for pediatric cancers, announced terms for its IPO on Friday. The New York, NY-based company plans to raise $80 million by offering 5.33 million shares at a price range of $14...read more
US IPO Weekly Recap: 4 IPOs pop 40% including Eventbrite, Farfetch and Elanco
Six IPOs raised $2.9 billion this week. Four traded up over 40%, and none finished the week below issue. Spun out of Eli Lilly, Elanco Animal Health (ELAN) priced above its range to raise $1.5 billion. The company popped 50% on its...read more
Pediatric cancer biotech Y-mAbs Therapeutics prices upsized IPO at $16 high end
Y-mAbs Therapeutics, a Phase 2 biotech developing monoclonal antibody therapies for pediatric cancers, raised $96 million by offering 6.0 million shares at $16, the high end of the $14 to $16 range. The company had originally planned to raise $80 million by...read more
US IPO Week Ahead: Eventbrite headlines 8-IPO week raising $3.3 billion
Eight IPOs are on the docket for the week ahead, raising a whopping $3.3 billion. Three deals are raising $500 million, but fast-growing ticketing platform Eventbrite (EB) should generate the most excitement. The largest, ...read more
Pediatric cancer biotech Y-mAbs Therapeutics sets terms for $80 million IPO
Y-mAbs Therapeutics, a phase 2 biotech developing monoclonal antibody therapies for pediatric cancers, announced terms for its IPO on Friday. The New York, NY-based company plans to raise $80 million by offering 5.33 million shares at a price range of $14...read more